Knowledge

Biological target

Source πŸ“

710:
Novelty of target and MoA is the second major potential advantage of PDD . In addition to identifying novel targets, PDD can contribute to improvements over existing therapies by identifying novel physiology for a known target, exploring 'undrugged' targets that belong to well known drug target
314:
on fish survival. Pharmaceuticals are usually found at ng/L to low-ΞΌg/L concentrations in the aquatic environment. Adverse effects may occur in non-target species as a consequence of specific drug target interactions. Therefore,
129:
change in the target is induced by the stimulus which results in a change in target function. This change in function can mimic the effect of the endogenous substance in which case the effect is referred to as
95:– A chemical reaction occurs between the stimulus and target in which the stimulus becomes chemically bonded to the target, but the reverse reaction also readily occurs in which the bond can be broken. 88:– A relatively weak interaction between the stimulus and the target where no chemical bond is formed between the two interacting partners and hence the interaction is completely reversible. 861:
Gunnarsson L, Jauhiainen A, Kristiansson E, Nerman O, Larsson DG (August 2008). "Evolutionary conservation of human drug targets in organisms used for environmental risk assessments".
333: 294:
These biological targets are conserved across species, making pharmaceutical pollution of the environment a danger to species who possess the same targets. For example, the synthetic
251:
approach. Potential drug targets are not necessarily disease causing but must by definition be disease modifying. An alternative means of identifying new drug targets is
904:
Larsson DG, Adolfsson-Erici M, Parkkonen J, Pettersson M, Berg AM, Olsson PE, FΓΆrlin L (April 1999). "Ethinyloestradiol β€” an undesired fish contraceptive?".
456: 247:
Identifying the biological origin of a disease, and the potential targets for intervention, is the first step in the discovery of a medicine using the
155:
research to describe the native protein in the body whose activity is modified by a drug resulting in a specific effect, which may be a desirable
110:
substances (such as activating hormones) from binding to the target. Depending on the nature of the target, this effect is referred as
81:, the drug or ligand) physically binds to ("hits") the biological target. The interaction between the substance and the target may be: 31:) is directed and/or binds, resulting in a change in its behavior or function. Examples of common classes of biological targets are 255:
based on phenotypic screening to identify "orphan" ligands whose targets are subsequently identified through target deconvolution.
815:
Jung HJ, Kwon HJ (2015). "Target deconvolution of bioactive small molecules: the heart of chemical biology and drug discovery".
587: 468: 439: 570:
Lundstrom K (2009). "An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs".
723:
Lee H, Lee JW (2016). "Target identification for biologically active small molecules using chemical biology approaches".
98:
irreversible covalent – The stimulus is permanently bound to the target through irreversible chemical bond formation.
387:
Moy VT, Florin EL, Gaub HE (October 1994). "Intermolecular forces and energies between ligands and receptors".
310:
of fish downstream from sewage treatment plants, thereby unbalancing reproduction and creating an additional
1033: 430:
Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G (2012). "Chapter 3: How drugs act: molecular aspects".
267: 319:
drug targets are likely to be associated with an increased risk for non-targeted pharmacological effects.
57:), or some other target of an external stimulus. Biological targets are most commonly proteins such as 231: 174: 316: 210: 711:
classes or discovering novel MoAs, including new ways of interfering with difficult-to-drug targets.
106:
There is no direct change in the biological target, but the binding of the substance prevents other
205: 40: 138:) or be the opposite of the endogenous substance which in the case of receptors is referred to as 980:
Kostich MS, Lazorchak JM (2008). "Risks to aquatic organisms posed by human pharmaceutical use".
66: 303: 307: 484:
Overington JP, Al-Lazikani B, Hopkins AL (December 2006). "How many drug targets are there?".
1028: 527:
Landry Y, Gies JP (February 2008). "Drugs and their molecular targets: an updated overview".
311: 24: 989: 944: 870: 396: 252: 248: 8: 111: 85: 993: 948: 874: 400: 840: 792: 767: 748: 701: 647: 622: 598: 552: 509: 352:
Raffa RB, Porreca F (1989). "Thermodynamic analysis of the drug-receptor interaction".
156: 917: 1005: 962: 886: 832: 797: 740: 693: 652: 603: 583: 556: 544: 540: 501: 464: 435: 412: 369: 365: 222: 126: 46: 1001: 752: 672:"Opportunities and challenges in phenotypic drug discovery: an industry perspective" 513: 39:. The definition is context-dependent, and can refer to the biological target of a 23:
is anything within a living organism to which some other entity (like an endogenous
997: 952: 913: 878: 844: 824: 787: 779: 732: 705: 683: 642: 634: 593: 575: 536: 493: 404: 361: 217: 135: 119: 115: 139: 579: 638: 328: 184: 160: 152: 107: 828: 736: 1022: 299: 92: 408: 1009: 966: 890: 836: 801: 744: 697: 656: 607: 548: 505: 36: 416: 373: 903: 688: 671: 196: 62: 434:. Edinburgh; New York: Elsevier/Churchill Livingstone. pp. 20–48. 957: 932: 882: 860: 783: 463:. Edinburgh; New York: Elsevier/Churchill Livingstone. pp. 6–19. 283: 497: 167:. The most common drug targets of currently marketed drugs include: 163:. In this context, the biological target is often referred to as a 295: 278: 192: 188: 16:
Part of an organism targeted by a ligand or drug to affect behavior
334:
Environmental impact of pharmaceuticals and personal care products
102:
Depending on the nature of the stimulus, the following can occur:
226: 131: 54: 50: 32: 574:. Methods in Molecular Biology. Vol. 552. pp. 51–66. 273: 180: 58: 768:"Identification of direct protein targets of small molecules" 483: 455:
Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G (2012).
43: 28: 930: 670:
Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M (2017).
933:"Repeating history: pharmaceuticals in the environment" 623:"Identifying druggable disease-modifying gene products" 931:
Ankley GT, Brooks BW, Huggett DB, Sumpter JP (2007).
263:
Databases containing biological targets information:
669: 454: 429: 448: 423: 151:The term "biological target" is frequently used in 856: 854: 765: 1020: 979: 851: 766:Lomenick B, Olsen RW, Huang J (January 2011). 620: 457:"Chapter 2: How drugs act: general principles" 759: 572:G Protein-Coupled Receptors in Drug Discovery 386: 242: 973: 924: 351: 563: 520: 477: 663: 526: 380: 345: 956: 808: 791: 687: 646: 614: 597: 569: 814: 716: 621:Dixon SJ, Stockwell BR (December 2009). 529:Fundamental & Clinical Pharmacology 289: 1021: 937:Environmental Science & Technology 863:Environmental Science & Technology 722: 982:The Science of the Total Environment 627:Current Opinion in Chemical Biology 13: 14: 1045: 306:, has been shown to increase the 541:10.1111/j.1472-8206.2007.00548.x 1002:10.1016/j.scitotenv.2007.09.008 897: 146: 817:Archives of Pharmacal Research 725:Archives of Pharmacal Research 676:Nature Reviews. Drug Discovery 486:Nature Reviews. Drug Discovery 1: 918:10.1016/S0166-445X(98)00112-X 339: 317:evolutionarily well-conserved 461:Rang and Dale's Pharmacology 432:Rang and Dale's Pharmacology 366:10.1016/0024-3205(89)90182-3 268:Therapeutic Targets Database 258: 72: 7: 580:10.1007/978-1-60327-317-6_4 322: 232:membrane transport proteins 175:G protein-coupled receptors 49:, the receptor target of a 10: 1050: 639:10.1016/j.cbpa.2009.08.003 243:Drug target identification 211:voltage-gated ion channels 829:10.1007/s12272-015-0618-3 737:10.1007/s12272-016-0791-z 218:nuclear hormone receptors 206:ligand-gated ion channels 177:(target of 50% of drugs) 41:pharmacologically active 409:10.1126/science.7939660 77:The external stimulus ( 304:17-R-ethinylestradiol 772:ACS Chemical Biology 689:10.1038/nrd.2017.111 290:Conservation ecology 253:forward pharmacology 249:reverse pharmacology 120:ion channel blockade 1034:Biology terminology 994:2008ScTEn.389..329K 949:2007EnST...41.8211A 875:2008EnST...42.5807G 401:1994Sci...266..257M 223:structural proteins 112:receptor antagonism 906:Aquatic Toxicology 312:selective pressure 157:therapeutic effect 958:10.1021/es072658j 883:10.1021/es8005173 869:(15): 5807–5813. 784:10.1021/cb100294v 589:978-1-60327-316-9 470:978-0-7020-3471-8 441:978-0-7020-3471-8 136:enzyme activation 116:enzyme inhibition 21:biological target 1041: 1014: 1013: 977: 971: 970: 960: 928: 922: 921: 901: 895: 894: 858: 849: 848: 812: 806: 805: 795: 763: 757: 756: 720: 714: 713: 691: 667: 661: 660: 650: 618: 612: 611: 601: 567: 561: 560: 524: 518: 517: 481: 475: 474: 452: 446: 445: 427: 421: 420: 384: 378: 377: 349: 132:receptor agonism 1049: 1048: 1044: 1043: 1042: 1040: 1039: 1038: 1019: 1018: 1017: 988:(2–3): 329–39. 978: 974: 929: 925: 902: 898: 859: 852: 813: 809: 764: 760: 731:(9): 1193–201. 721: 717: 668: 664: 633:(5–6): 549–55. 619: 615: 590: 568: 564: 525: 521: 498:10.1038/nrd2199 482: 478: 471: 453: 449: 442: 428: 424: 395:(5183): 257–9. 385: 381: 350: 346: 342: 325: 292: 261: 245: 185:protein kinases 159:or an unwanted 149: 140:inverse agonism 134:(or channel or 75: 17: 12: 11: 5: 1047: 1037: 1036: 1031: 1016: 1015: 972: 943:(24): 8211–7. 923: 912:(2–3): 91–97. 896: 850: 823:(9): 1627–41. 807: 758: 715: 682:(8): 531–543. 662: 613: 588: 562: 519: 476: 469: 447: 440: 422: 379: 343: 341: 338: 337: 336: 331: 329:Drug discovery 324: 321: 300:contraceptives 291: 288: 287: 286: 281: 276: 271: 260: 257: 244: 241: 240: 239: 236: 235: 234: 229: 220: 215: 214: 213: 208: 200: 178: 161:adverse effect 153:pharmaceutical 148: 145: 144: 143: 127:conformational 123: 100: 99: 96: 89: 74: 71: 15: 9: 6: 4: 3: 2: 1046: 1035: 1032: 1030: 1027: 1026: 1024: 1011: 1007: 1003: 999: 995: 991: 987: 983: 976: 968: 964: 959: 954: 950: 946: 942: 938: 934: 927: 919: 915: 911: 907: 900: 892: 888: 884: 880: 876: 872: 868: 864: 857: 855: 846: 842: 838: 834: 830: 826: 822: 818: 811: 803: 799: 794: 789: 785: 781: 777: 773: 769: 762: 754: 750: 746: 742: 738: 734: 730: 726: 719: 712: 707: 703: 699: 695: 690: 685: 681: 677: 673: 666: 658: 654: 649: 644: 640: 636: 632: 628: 624: 617: 609: 605: 600: 595: 591: 585: 581: 577: 573: 566: 558: 554: 550: 546: 542: 538: 534: 530: 523: 515: 511: 507: 503: 499: 495: 492:(12): 993–6. 491: 487: 480: 472: 466: 462: 458: 451: 443: 437: 433: 426: 418: 414: 410: 406: 402: 398: 394: 390: 383: 375: 371: 367: 363: 360:(4): 245–58. 359: 355: 354:Life Sciences 348: 344: 335: 332: 330: 327: 326: 320: 318: 313: 309: 305: 301: 297: 285: 282: 280: 277: 275: 272: 269: 266: 265: 264: 256: 254: 250: 238:nucleic acids 237: 233: 230: 228: 224: 221: 219: 216: 212: 209: 207: 204: 203: 202:ion channels 201: 198: 194: 190: 186: 182: 179: 176: 173: 172: 170: 169: 168: 166: 162: 158: 154: 141: 137: 133: 128: 124: 121: 117: 113: 109: 105: 104: 103: 97: 94: 90: 87: 84: 83: 82: 80: 70: 68: 64: 60: 56: 52: 48: 45: 42: 38: 37:nucleic acids 34: 30: 26: 22: 1029:Pharmacology 985: 981: 975: 940: 936: 926: 909: 905: 899: 866: 862: 820: 816: 810: 778:(1): 34–46. 775: 771: 761: 728: 724: 718: 709: 679: 675: 665: 630: 626: 616: 571: 565: 532: 528: 522: 489: 485: 479: 460: 450: 431: 425: 392: 388: 382: 357: 353: 347: 308:feminization 293: 262: 246: 197:phosphatases 183:(especially 164: 150: 147:Drug targets 101: 78: 76: 63:ion channels 20: 18: 535:(1): 1–18. 165:drug target 91:reversible 86:noncovalent 1023:Categories 340:References 284:Binding DB 108:endogenous 557:205630866 298:in human 259:Databases 193:esterases 189:proteases 171:proteins 73:Mechanism 67:receptors 1010:17936335 967:18200843 891:18754513 837:26040984 802:21077692 753:13577563 745:27387321 698:28685762 657:19740696 608:19513641 549:18251718 514:11979420 506:17139284 323:See also 296:estrogen 279:DrugBank 225:such as 93:covalent 47:compound 33:proteins 990:Bibcode 945:Bibcode 871:Bibcode 845:2399601 793:3031183 706:6180139 648:2787993 599:7122359 417:7939660 397:Bibcode 389:Science 374:2536880 274:DrugMap 227:tubulin 181:enzymes 59:enzymes 55:insulin 51:hormone 1008:  965:  889:  843:  835:  800:  790:  751:  743:  704:  696:  655:  645:  606:  596:  586:  555:  547:  512:  504:  467:  438:  415:  372:  195:, and 65:, and 53:(like 25:ligand 841:S2CID 749:S2CID 702:S2CID 553:S2CID 510:S2CID 270:(TTD) 118:, or 27:or a 1006:PMID 963:PMID 887:PMID 833:PMID 798:PMID 741:PMID 694:PMID 653:PMID 604:PMID 584:ISBN 545:PMID 502:PMID 465:ISBN 436:ISBN 413:PMID 370:PMID 79:i.e. 44:drug 35:and 29:drug 998:doi 986:389 953:doi 914:doi 879:doi 825:doi 788:PMC 780:doi 733:doi 684:doi 643:PMC 635:doi 594:PMC 576:doi 537:doi 494:doi 405:doi 393:266 362:doi 1025:: 1004:. 996:. 984:. 961:. 951:. 941:41 939:. 935:. 910:45 908:. 885:. 877:. 867:42 865:. 853:^ 839:. 831:. 821:38 819:. 796:. 786:. 774:. 770:. 747:. 739:. 729:39 727:. 708:. 700:. 692:. 680:16 678:. 674:. 651:. 641:. 631:13 629:. 625:. 602:. 592:. 582:. 551:. 543:. 533:22 531:. 508:. 500:. 488:. 459:. 411:. 403:. 391:. 368:. 358:44 356:. 302:, 191:, 187:, 125:A 114:, 69:. 61:, 19:A 1012:. 1000:: 992:: 969:. 955:: 947:: 920:. 916:: 893:. 881:: 873:: 847:. 827:: 804:. 782:: 776:6 755:. 735:: 686:: 659:. 637:: 610:. 578:: 559:. 539:: 516:. 496:: 490:5 473:. 444:. 419:. 407:: 399:: 376:. 364:: 199:) 142:. 122:.

Index

ligand
drug
proteins
nucleic acids
pharmacologically active
drug
compound
hormone
insulin
enzymes
ion channels
receptors
noncovalent
covalent
endogenous
receptor antagonism
enzyme inhibition
ion channel blockade
conformational
receptor agonism
enzyme activation
inverse agonism
pharmaceutical
therapeutic effect
adverse effect
G protein-coupled receptors
enzymes
protein kinases
proteases
esterases

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.

↑